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Abstract
Background: Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication that can be
difficult to treat; moreover, determination of the pathophysiological type is difficult. We report a rare case of a
patient who developed two types of Epstein–Barr virus (EBV)-negative PTLD following living donor liver
transplantation (LDLT).
Case presentation: A 64-year-old man underwent LDLT for acute fulminant hepatitis B. Sixty-five months later, he
developed EBV-negative monomorphic B cell PTLD. Reduction of immunosuppressive therapy and chemotherapy
with rituximab resulted in a partial response. He received radioimmunotherapy with yttrium-90-ibritumomab
tiuxetan, which was effective for all lesions, except for the splenic hilar lesion, which enlarged and seemed to
penetrate the stomach. Therefore, he underwent resection of the pancreatic tail with splenectomy and partial
gastrectomy. The pathological diagnosis was EBV-negative classical Hodgkin lymphoma (cHL)-type PTLD.
Conclusions: This patient showed an unexpected course of PTLD, from both a clinical and pathological
perspective. There are no prior reports of an adult case of EBV-negative cHL-type PTLD coexisting with EBV-negative
monomorphic B cell PTLD. When a strange and refractory lesion persists despite effective therapy for PTLD, we
must consider the possibility of another type of PTLD within the residual lesion.
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Background
Post-transplant lymphoproliferative disorder (PTLD) and
susceptibility to infection are important and severe com-
plications that occur secondary to the clinical use of po-
tent immunosuppressive agents. According to 2008
World Health Organization classification, PTLD is cate-
gorized as one of the four major histological forms: early
lesion, polymorphic PTLD, monomorphic PTLD, and
classical Hodgkin lymphoma-type PTLD (cHL). In the
clinic settings, monomorphic PTLD is observed most
frequently, whereas cHL-type PTLD is uncommon [1]. It
is suggested that most PTLD cases have a strong rela-
tionship with Epstein–Barr virus (EBV) [2]. Here we re-
port a rare case of EBV-negative cHL-type PTLD,
coexisting with EBV-negative monomorphic B cell PTLD
following living donor liver transplantation (LDLT).
Case presentation
A 64-year-old man underwent LDLT from his daughter in
May 2009 for acute fulminant hepatitis B. Both the recipi-
ent and donor had prior infection with EBV. The initial
immunosuppression consisted of methylprednisolone and
tacrolimus, with induction therapy using basiliximab. The
trough level of tacrolimus was adjusted within the range
of 3–4 ng/ml. Thereafter, he received tacrolimus (3 mg/
day) and mycophenolate mofetil (500 mg/day), which kept
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the graft function in good condition. He had no history of
immunological rejection in post-operative course until
65 months following LDLT, when he noted fever, pain in
the left epigastrium, and nausea. He underwent computed
tomography (CT) as a follow-up just 1 year before the on-
set of this symptom, but no abnormal findings were found
in particular. CT revealed systemic lymphadenopathy,
mainly in the abdomen, mediastinum, and bilateral cer-
vical lymph nodes. In the splenic hilum, there was a large
lymphadenopathy that compressed the stomach (Fig. 1a).
Upper gastrointestinal endoscopy revealed that a part of
the gastric wall was compressed by the large lymphadenop-
athy in the splenic hilum on CT. We performed a biopsy
from the lesion of the stomach; however, the result was in-
flammatory mucosa only, and we could not find a definitive
diagnosis. Fluorodeoxyglucose positron emission tomog-
raphy (FDG-PET) also showed systemic uptake corre-
sponding to the area of lymphadenopathy on CT (Fig. 1b).
His EBV viral load in the blood was undetectable. Biopsy
from the cervical lymph node showed diffuse distortion of
architecture, with hyperplasia of large and pleomorphic
atypical lymphoid cells (Fig. 2a).
Flow cytometry for abnormal B cell populations re-
vealed the following phenotypes: CD20+, CD10+, CD3−,
CD56−, CD4−, and CD30−. Antibodies used for immuno-
histochemistry showed CD20+, CD10+, CD3−, CD5−,
CD45+, CD56−, CD79a+, bcl2−, and bcl6+ (weak) (Fig. 2b
and Table 1). EBV-encoded ribonucleic acid in situ
hybridization (EBER-ISH) was negative in the tumor cells
(Fig. 2c). Chromosome analysis demonstrated
47,X,−Y,+X,add(3)(q27),+ 5,del(6)(p23),add(10)(q26). Poly-
merase chain reaction analysis showed rearrangement of
the IgH gene. The histopathological diagnosis was follicu-
lar lymphoma (FL) grade 3B, with split signals of BCL6
gene defined by fluorescence in situ hybridization (FISH)
(Fig. 3a). From these findings, he was diagnosed with
EBV-negative monomorphic B-cell PTLD.
The clinical course with the progress of serum lactate
dehydrogenase and soluble interleukin-2 receptor is
shown in Fig. 4. His immunosuppressive therapy was re-
duced. His target trough level of tacrolimus was adjusted
to ≤ 4 ng/ml at the onset of PTLD, which is the target
trough level during the treatment of PTLD at our insti-
tution. Therefore, we elected to discontinue mycopheno-
late mofetil without changing the dose of tacrolimus.
Moreover, he received prednisolone, but there was min-
imal response. Thereafter, he received rituximab therapy;
unfortunately, this treatment was slightly effective and
the splenic hilar lymph node remained unchanged in
size. Subsequently, he received radioimmunotherapy
with yttrium-90-ibritumomab tiuxetan (90Y-IT). The
agent 90Y-IT contains the anti-CD20 monoclonal anti-
body ibritumomab covalently bonded to the chelating
agent tiuxetan and radiolabeled with 90Y. Three months
after the therapy, the systemic lymphadenopathy re-
solved almost completely, except for the splenic hilar le-
sion, which seemed to progress uncontrollably and
penetrate the stomach (Fig. 5a, b).
The patient underwent resection of the pancreatic
tail with splenectomy and partial gastrectomy
(Fig. 6a–c). The splenic hilar lesion was exposed in
the lumen of the stomach (Fig. 6a). It was enlarged
and compressed its surroundings, penetrating the
stomach (Fig. 6b, c). Morphologically, the specimen
revealed few large dyskaryotic or multinucleated
atypical lymphoid cells infiltrating the stomach wall,
pancreas, and splenic artery and vein (Fig. 7a). The
atypical lymphoid cells were suggested to be Hodg-
kin/Reed–Sternberg cells. Antibodies used for immu-
nohistochemistry showed CD20−, CD3−, CD5−,
Fig. 1 Imaging findings at the time of admission. a The first computed tomography (CT) demonstrated systemic lymphadenopathy, mainly in the
abdomen. The large lymphadenopathy in the splenic hilum seemed to be a gastric submucosal tumor. b Fluorodeoxyglucose positron emission
tomography showed systemic uptake, mainly in the intraabdominal lymph nodes. The largest uptake corresponded to the lymphadenopathy in
the splenic hilum, as observed on CT
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CD45+, CD56−, and CD79a+ and weak positivities
for both CD30 and CD10 (Fig. 7b, c and Table 1).
To reveal the relationship between the Hodgkin cells
and the underlying monomorphic PTLD, we per-
formed a double labeling detection method that
combined FISH for breakpoint in BCL6 and immu-
nohistochemical staining for CD30 on the Hodgkin
cells, revealing rearrangement of BCL6 (Fig. 3b).
EBER-ISH showed negativity in the tumor cells
(Fig. 7d). His preoperative EBV viral load in the
blood was also undetectable. Therefore, we diag-
nosed EBV-negative cHL-type PTLD.
Six months after the surgery, surveillance CT showed
no recurrence of PTLD; the patient then resumed tacro-
limus (3 mg/day).
Discussion
PTLD is regarded as distinct from hematological malig-
nancies, which develop in non-transplant recipients [1].
PTLD has various origins; approximately 85% are B cell
proliferations, 14% are T cell proliferations, and the
remaining 1% are NK cell or plasmacyte proliferations [3].
The main risk factors for PTLD are age, EBV status, use of
immunosuppressive agents, and the type of organ
transplanted [2]. Most adults with PTLD are EBV-negative,
whereas children with PTLD tend to be EBV-positive [1]. As
a patient receives higher doses of immunosuppressive agents,
the frequency of developing PTLD increases and the time to
onset of PTLD shortens [4]. In our patient, therapeutic drug
monitoring kept the levels of immunosuppressive agents in
the appropriate range. There is a difference in the prevalence
of PTLD according to the type of organ that is transplanted;
the small intestine is the most affected (20%), followed by
the lungs at 4–10%, heart at 1–6%, liver and kidneys at 1–
3%, and other organs at an average of 10% [5]. At our
institution, we encountered 95 pediatric cases (< 18 years
old) and 75 adult cases who underwent LDLT between July
1991 and December 2017. Among these, seven pediatric pa-
tients (7%) and two adult cases (3%) developed PTLD.
Fig. 2 Microscopic findings of biopsy from the cervical lymph node. a Hyperplasia of large and pleomorphic atypical lymphoid cells was
observed in the lymph nodes (hematoxylin/eosin). b Immunohistochemical staining was positive for CD20. c Epstein–Barr virus-encoded
ribonucleic acid in situ hybridization was negative in the tumor cells
Table 1 Immunohistochemical findings of each post-transplant
lymphoproliferative disorder (PTLD)
Antibody 1st PTLD 2nd PTLD
CD3 – –
CD5 – –
CD10 + +
CD20 + –
CD30 None +
CD45 + +
CD56 – –
CD79a + +
1st PTLD Epstein–Barr virus (EBV)-negative monomorphic B-cell PTLD, 2nd PTLD
EBV-negative classical Hodgkin lymphoma-type PTLD
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PTLD has a strong relationship with EBV, particularly in
B cell proliferations [2]. Krasuska-Sławińska et al. reported
that EBV has been identified in 90% of B cell-proliferating
PTLDs [6]. In general, the time of development of
EBV-negative PTLD occurs later than that of EBV-positive
PTLD [7]. These features were seen in our case.
EBV-negative PTLD remains lesser elucidated than
EBV-positive PTLD. Among the nine PTLD cases that we
have encountered at our institution, all seven pediatric
PTLDs were EBV-positive, whereas both adult cases were
EBV-negative. In general, the first choice of treatment for
PTLD is the reduction of immunosuppression. Rituximab is
theoretically effective for CD20-positive PTLD but is only
effective in approximately half of these patients [8]. In our
case, considering that this patient was older and that the
type of PTLD would be enough response by steroids, we
did not initially use rituximab. However, because it was not
possible to attain the expected response, we used rituximab.
Recently, 90Y-IT has been reported to be effective in PTLD
patients who were resistant to rituximab [8] as well as in pa-
tients with CD20-positive cHL [9]. In our case, 90Y-IT
seemed to be effective for monomorphic PTLD but ineffect-
ive for cHL-type PTLD because of the negativity to CD20.
Surgical therapy can also be effective and provide the cor-
rect diagnosis for localized PTLD, like in our cases [10]. His
target trough of tacrolimus has been adjusted at a low level
of ≤4 ng/ml both before and during PTLD [11]. Moreover,
because he did not show recurrence and rejection findings
after surgery, there was no need to change the target trough,
and thus, he was observed at the same dose of tacrolimus.
Fig. 3 Fluorescence in situ hybridization (FISH) findings of each post-transplant lymphoproliferative disorder (PTLD). a FISH of monomorphic B
cell (follicular lymphoma type) PTLD. The split signals (green and yellow triangles) indicating a rearrangement of BCL6 in the tumor cell. b Double
labeling detection method that combines FISH for rearrangement of BCL6 and immunohistochemical staining for CD30 of classical Hodgkin
lymphoma-type PTLD. In the Hodgkin cells, there were the split signals (green and yellow triangles) indicating a rearrangement of BCL6, and the
other signal (red triangle) indicating an immunohistochemical positivity for CD30
Fig. 4 Clinical course
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For data pertaining to adjuvant chemotherapy, we searched
PubMed and found no studies that reported on using adju-
vant chemotherapy for PTLD after curative surgery. Further
cases and studies are needed to reveal the effectiveness of
adjuvant chemotherapy for PTLD after surgery.
Our case exhibited various histopathological types of
PTLD. It was difficult to determine whether the cHL-type
PTLD developed after the remission of monomorphic B cell
PTLD; the two types of PTLD might have coexisted from
the beginning. There are reports of two pediatric liver
Fig. 5 Preoperative image findings. a Preoperative computerized tomography and b fluorodeoxyglucose positron emission tomography
demonstrated almost complete resolution of the systemic lymphadenopathy, except for the splenic hilar lymph node
Fig. 6 Macroscopic findings of the excised specimen. a A mass was exposed in the lumen of the stomach (white arrow). b, c The splenic hilar
lesion was enlarged to compress the surroundings, penetrating the stomach (black arrow)
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transplant patients [12–14] and one adult patient [15] who
developed cHL-type PTLD subsequent to another type of
PTLD (Table 2); all cases developed EBV-positive cHL-type
PTLD after EBV-positive polymorphic B-cell PTLD [12, 14,
15]. Our case was very interesting due to simultaneous
presentation of EBV-negative cHL-type PTLD and
EBV-negative monomorphic B-cell PTLD.
In our case, the monomorphic PTLD showed rearrange-
ment of BCL6 by FISH (Fig. 3a), whereas the cHL-type
PTLD showed rearrangement of BCL6 during the double
labeling detection method that combined FISH and immu-
nohistochemical staining (Fig. 3b). From these results, we
concluded that these two PTLDs might have a common
origin. Several reports have shown that cHL and FL are
Fig. 7 Microscopic findings of the excised specimen. a A few large dyskaryotic or multinucleated atypical lymphoid cells, including Reed–
Sternberg cells, were observed (hematoxylin/eosin). Immunohistochemical staining revealed that they were negative for b CD20 and positive for
c CD30. The results of other immunostaining were described in Table 1. d Epstein–Barr virus-encoded ribonucleic acid in situ hybridization was
negative in the tumor cells
Table 2 Features of classical Hodgkin lymphoma (cHL)-type post-transplant lymphoproliferative disorder (PTLD) subsequent to
another PTLD following liver transplantation
Case
no.
Age/sex Interval Diagnosis EBV
positivity
Symptoms except
lymphoadenopathy
Treatment Outcome Reference
1 64 years/
M
5 years and 5 months
from transplant
monomorphic
PTLD
− Fever, abdominal
pain
Reduction of immunosupression,
rituximab, 90Y-IT
* Current
case
1 year from the 1st
PTLD
cHL PTLD − Fever Surgery CR
2 28 years/
F
2 years and 2 months
from transplant
Polymorphic
PTLD
+ Fever Reduction of immunosupression,
acyclovir
CR 15
2 years and 5 months
from the 1st PTLD
cHL PTLD + Fever, splenomegaly Reduction of immunosupression,
acyclovir, MOPP, splenectomy
CR
3 9 years/
M
8 years from transplant Polymorphic
PTLD
+ Enlarged tonsil,
adenoid
Reduction of immunosupression,
acyclovir
CR 12
6 years and 10 months
from the 1st PTLD
cHL PTLD + Mediastinal mass COPP, ABV CR
4 6 years/
M
4 years and 2 months
from transplant
Polymorphic
PTLD
+ None Reduction of immunosupression,
gancyclovir
CR 14
1 year and 6 months
from the 1st PTLD
cHL PTLD + Fever MOPP, ABVD, radiation CR
PTLD post-transplant lymphoproliferative disorder, cHL classical Hodgkin lymphoma, M male, F female, 90Y-IT yttrium-90-ibritumomab tiuxetan, MOPP
mechlorethamine, vincristine, procarbazine, prednisone, COPP cyclophosphamide, vincristin, procarbazine, prednisone, ABV doxorubicin, bleomycin, vinblastine,
ABVD doxorubicin, bleomycin, vinblastine, dacarbazine, CR complete remission
*The systemic lymphadenopathy resolved almost completely, except for the splenic hilar lesion composed of cHL-type PTLD
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derived from a shared germinal center B cell clone [16].
Nakamura et al. reported that FL converted to cHL by
proving a rearrangement of BCL2 [17]. A rearrangement of
BCL6 is mainly observed in FL or diffuse large B cell
lymphoma and is rarely observed in cHL. With regard to
PTLD cases, Poirel et al. reported three cases of mono-
morphic type and one case of cHL type with rearrangement
of BCL6 [18]. Five percent of patients who developed
EBV-related PTLD developed another EBV-related PTLD,
but there are no reports that can prove a causal relationship
between the two types of PTLD [19]. To the best of our
knowledge, there has been no report of EBV-negative
monomorphic B cell PTLD converting to EBV-negative
cHL-type PTLD by a rearrangement of BCL6 in the same
patient following SOT.
Conclusions
When a strange and refractory PTLD lesion persists des-
pite effective therapy, practitioners should consider the
possibility of another type of PTLD in the residual
lesion.
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